Literature DB >> 15140116

Is the incidence and prevalence of inhibitors greater with recombinant products? No.

J M Lusher1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15140116     DOI： 10.1111/j.1538-7836.2004.00729.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  5 in total

1.  Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.

Authors:  Lingfei Xu; Timothy C Nichols; Rita Sarkar; Stephanie McCorquodale; Dwight A Bellinger; Katherine P Ponder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

2.  Gene therapy: the promise of a permanent cure.

Authors:  Christopher D Porada; Christopher Stem; Graca Almeida-Porada
Journal:  N C Med J       Date:  2013 Nov-Dec

3.  Haemophilia A in two premature infants.

Authors:  Christoph Bidlingmaier; Frauke Bergmann; Karin Kurnik
Journal:  Eur J Pediatr       Date:  2004-12-03       Impact factor: 3.183

Review 4.  Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.

Authors:  Ai Hong Zhang; Jonathan Skupsky; David W Scott
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

5.  The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.

Authors:  Tarek Owaidah; Abdulkareem Al Momen; Hazzaa Alzahrani; Abdulrahman Almusa; Fawaz Alkasim; Ahmed Tarawah; Randa Al Nouno; Fatima Al Batniji; Fahad Alothman; Ali Alomari; Saud Abu-Herbish; Mahmoud Abu-Riash; Khawar Siddiqui; Mansor Ahmed; S Y Mohamed; Mahasen Saleh
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.